
Sign up to save your podcasts
Or


Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet Group5
11 ratings
Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

7,731 Listeners

320 Listeners

112,597 Listeners

187 Listeners

365 Listeners

62,560 Listeners

57 Listeners

22 Listeners

0 Listeners

0 Listeners

2 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

215 Listeners

0 Listeners

0 Listeners